ADC
AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer
Datroway; Datopotamab deruxtecan; triple-negative breast cancer; ADC; AstraZeneca; Daiichi Sankyo; clinical trial; overall survival; chemotherapy; TROP2; phase 3 trial; immunotherapy; TROPION-Breast02
Genmab Abandons ADC Asset Acquired in $1.8B ProfoundBio Deal
Genmab; ProfoundBio; antibody-drug conjugates; ADC; acquisition; oncology; Rina-S
CytomX Continues Phase I ADC Study After Patient Death
CytomX; CX-2051; Phase I; ADC; colorectal cancer; patient death; acute kidney injury; clinical trial; safety; FDA; trial continuation
NextCure Partners with Simcere for Novel ADC in $745M Deal
NextCure; Simcere; Antibody-Drug Conjugate; ADC; SIM0505; CDH6 Targeting
AbbVie Advances Solid Tumor Program with FDA Approval of Emrelis for Lung Cancer
AbbVie; Emrelis; FDA Approval; ADC; solid tumor; lung cancer; non-small cell lung cancer; c-Met overexpression; telisotuzumab vedotin-tllv; accelerated approval
Otsuka’s Taiho pays $400M for Swiss partner to ‘turbocharge’ 3 ADCs to clinic
Araris, Taiho, Antibody-Drug Conjugates, Otsuka ‘s, Acquisition (action), ADCs, ADC
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership
Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline
Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate
FDA Clears BioNTech-MediLink ADC Trial to Resume with Reduced Doses
BioNTech, MediLink, ADC trial, FDA approval, lower doses, cancer treatment, HER3, patient safety